Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents.

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A minimum of two psychostimulant trials should be instituted before a child's symptoms of ADHD are considered treatment refractory. Clinical issues of diagnostic accuracy, comorbid disorders, psychosocial factors, medication compliance, symptoms across settings, and behavioral treatment should be addressed before initiating alternative medication trials. With the exception of tricyclic antidepressants, there is a paucity of controlled studies with adequate sample size to support the efficacy and safety of nonstimulant medications for the treatment of childhood ADHD. In this article, data on medications for treatment refractory ADHD in children and adolescents are presented and treatment strategies are discussed.

Original languageEnglish (US)
Pages (from-to)130-142
Number of pages13
JournalPsychopharmacology bulletin
Volume36
Issue number1
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents.'. Together they form a unique fingerprint.

  • Cite this